

## **REMARKS**

### **Restriction Requirement**

The Examiner has required restriction to one of four groups:

Group I: Claims 1-9 and 41-46, drawn to a use of a phosphodiesterase antagonist.

Group II: Claims 10-16, drawn to a composition comprising a phosphodiesterase antagonist.

Group III: Claims 17-18, drawn to a kit comprising a phosphodiesterase antagonist.

Group IV: Claims 19-40 and 47-64, drawn to a method of reducing insulin resistance comprising administering a phosphodiesterase antagonist.

Without acquiescing to the statements made in the Restriction Requirement, Applicants hereby elect the claims of Group IV (claims 19-40 and 47-64) without traverse.

### **Amendments to the Claims**

In view of Applicants' election of Group IV claims, please cancel claims 1-18 and 41-46 (Groups I to III) without prejudice or disclaimer. Applicants reserve the right to pursue cancelled subject matter in one or more divisional applications.

Applicants have amended claims 23-31, 35, 37-40, 47-50 and 61-64. Support for the amendments can be found throughout the application, including at page 10, line 46 to page 11, line 7.

Upon entry of the amendment, Group IV claims 19-40 and 47-64 will be pending.


**SUMMARY**

In view of the foregoing, Applicants believe that the claims are in condition for allowance and such action is respectfully requested. If the Examiner believes a telephone conference would advance the prosecution of this application, the Examiner is invited to telephone the undersigned at the below-listed telephone number.

Respectfully submitted,

MERCHANT & GOULD P.C.  
P.O. Box 2903  
Minneapolis, Minnesota 55402-0903  
(612) 332-5300

Date: November 2, 2007

  
\_\_\_\_\_  
Brian R. Dorn, Ph.D.  
Reg. No. 57,395